Antimicrobial Susceptibility and Multiplex PCR Screening of AmpC Genes From Isolates of Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens

Chih-Chauan Kao, Meei-Fang Liu, Chin-Fu Lin, Yi-Ching Huang, Po-Yu Liu, Ching-Wen Chang, Zhi-Yuan Shih

BACKGROUND/PURPOSE: The emergence of multiple drug resistance in Enterobacteriaceae is of particular concern. The aim of this study was to evaluate the antimicrobial susceptibility and screen for the ampC gene in three members of the Enterobacteriaceae family (Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens) found at Taichung Veterans General Hospital during the past 5 years using multiplex polymerase chain reaction (PCR).

METHODS: The susceptibility of thirty isolates from each of the three Enterobacteriaceae family members to five antimicrobial agents (ceftazidime, flomoxef, imipenem, moxifloxacin, and colistin) was assessed. The susceptibility was analyzed by disk diffusion, screening and confirmatory tests for extended-spectrum β-lactamases (ESBL) and minimum inhibitory concentration tests according to the recommendations of the Clinical and Laboratory Standards Institute. The detection of ampC genes (3 families, including DHA, EBC and CIT) was performed by multiplex PCR. To detect the coexistence of ESBL genes, PCR was performed using five primer pairs: TEM, SHV, SHV-5, CTX-M-3, and CTX-M-14.

RESULTS: Of the 90 isolates, 53 (58.9%) were positive in the screening test for ESBL. Resistance genes were detected in 12 (22.6%) of these isolates: ampC gene of DHA type in one E. cloacae isolate and EBC type in three E. cloacae isolates; ampC gene of CIT type in four C. freundii isolates; CTX-M-3-like in one C. freundii isolate and one S. marcescens isolate; TEM in three E. cloacae isolates, three C. freundii isolates and two S. marcescens isolates; SHV in one C. freundii isolate.

CONCLUSION: Antibiotic phenotypes cannot accurately distinguish the resistance mechanisms caused by ampC or ESBL, and especially in ESBL-ampC combinations. However, PCR is a useful technique for the identification of the different types of resistance genes.

KEYWORDS: AmpC, Citrobacter, Enterobacter, extended-spectrum β-lactamases, Serratia

*Corresponding author. Section of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, 160 Section 3, Chung-Kang Road, Taichung, 40705 Taiwan.

E-mail: cylindro@vghtc.gov.tw

Article History:
Received: Apr 30, 2009
Revised: May 14, 2009
Accepted: Jun 23, 2009
Introduction

Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens, and Citrobacter freundii account for the majority of Enterobacteriaceae isolated from clinical specimens. The emergence of multidrug resistant Enterobacteriaceae is of particular concern because of the potential for widespread dissemination, and difficulties in treating infected patients.1,2 The majority of plasmid-mediated ampC genes are found in nosocomial isolates of E. coli and K. pneumoniae. E. cloacae, C. freundii, S. marcescens, and Morganella morganii are characterized by chromosomally encoded AmpC β-lactamases and possess the ability to develop resistance upon exposure to broad-spectrum cephalosporins.3 These genes can confer broad-spectrum resistance to most β-lactams (other than ceftime and carbapenems) and hence pose a major therapeutic challenge.4,5 According to the criteria of the Clinical and Laboratory Standards Institute (CLSI),6 all isolates with minimum inhibitory concentrations (MICs) ≥ 2 μg/mL for ceftazidime, ceftriaxone, cefotaxime or aztreonam are potential extended spectrum β-lactamase (ESBL) producers. The CLSI recommends that a confirmatory clavulanic acid inhibition test be performed on these “screen test”-positive clinical isolates before reporting the susceptibility results for cephalosporins, and aztreonam.6 Enterobacteriaceae isolates with a positive screen test of ESBL phenotype, but a negative ESBL confirmatory test, are potential candidates for production of the AmpC enzyme, either mediated by chromosomal depression or transferred by a plasmid.7 Many clinical microbiologists appear to be unaware of the presence of plasmid-mediated AmpC β-lactamase enzymes in resistant isolates because phenotypic detection can be difficult and the strains may be misidentified as ESBL producers.8 Many methods for the detection of ESBLs, plasmid-mediated AmpC β-lactamases, and carbapenemases have been proposed. However, some of these procedures are technically demanding and time-consuming, others are hard to interpret, and still others require specialized reagents or reagents that are difficult to obtain.9

The presence of multiple β-lactamases within one organism (e.g. multiple ESBLs or ESBL-AmpC combinations) can make phenotypic identification difficult.10 Unfortunately, for these reasons, plasmid-mediated AmpC β-lactamase resistance goes undetected in most clinical laboratories.10 A multiplex polymerase chain reaction (PCR) method has been developed using six primer pairs to detect plasmid-mediated ampC genes. This technique is capable of identifying the family-specific ampC gene responsible for AmpC β-lactamase expression.11 Seventeen of 110 (15.5%) E. cloacae isolates from a Central Taiwan hospital were identified as ESBL-producers (predominantly SHV-12, with some isolates also producing CTX-M-3 and CTXM-9).7 Fifteen of 123 (12.2%) S. marcescens isolates from the same hospital were ESBL-producers, and all carried CTX-M-3.12 In a study from Northern Taiwan, SHV-12 was present in 26 isolates of E. cloacae, with the coexistence of CTX-M-3 in three of the isolates.13 However, studies of the AmpC β-lactamases present in Enterobacteriaceae has not been performed in Taiwan. The aim of this study was to evaluate the antimicrobial susceptibility of three members of the Enterobacteriaceae family (E. cloacae, C. freundii, and S. marcescens) found in Taichung Veterans General Hospital (TCVGH) during the past 5 years, and to screen for the related ampC resistant genes using multiplex PCR.

Materials and Methods

Isolates

Thirty isolates of each of the E. cloacae, C. freundii, and S. marcescens were collected from the Microbiology Laboratory of TCVGH between 2003 and 2007. All isolates were collected from blood specimens.

Screening test of ESBL phenotype

Screening tests were performed on all the isolates as follows: the MICs for ceftazidime were determined using the E-test (AB BIODISK, Solna, Sweden). Disk diffusion tests for ceftazidime and cefotaxime were performed according to CLSI recommendations.6 An isolate was considered positive if the MIC for ceftazidime was ≥ 2 μg/mL, if the inhibition zone for ceftazidime was ≤ 22 mm, or the inhibition zone for cefotaxime was ≤ 27 mm.

Confirmatory test

All isolates with a positive screening test were further tested using the confirmatory test according to CLSI
recommendations. An isolate was considered to have a positive confirmatory test if it showed a ≥5 mm increase in zone diameter for either ceftazidime or cefotaxime tested in combination with clavulanic acid versus its zone when tested alone.

Susceptibility test
The MICs of five antimicrobial agents; flomoxef (Shionogi, Osaka, Japan), imipenem (MSD, Rahway, NJ, USA), moxifloxacin (Bayer, Leverkusen, Germany), colistin (TTY, Hsinchu, Taiwan) and ceftazidime (GSK, UK) were assessed using the broth microdilution method according to CLSI recommendations. The antibiotics were serially diluted two-fold in 50 μL of cation-adjusted Mueller-Hinton broth. The final range of antibiotic concentrations was 0.01–256 μg/mL. The bacterial suspension was prepared from actively growing bacteria in 5 mL of cation-adjusted Mueller-Hinton broth, and diluted to a bacterial cell density of 10⁶ colony forming units (CFU)/mL. Five μL of bacterial suspension was then added to wells containing 100 μL of serially diluted antimicrobial agents to yield a final inoculum of approximately 5 x 10⁴ CFU/mL. The MICs were read after overnight incubation (18–24 hours) at 35⁰C. All MICs were determined in duplicate. E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the quality control strains.

Multiplex PCR protocol for detection of AmpC genes
Total bacterial DNA was prepared using guanidinium thiocyanate as previously described. PCR was performed in a final volume of 50 μL. The primers used for PCR amplification are listed in Table 1. Each reaction contained 45 μL of the master mix [20 mM Tris-HCl (pH 8.4), 50 mM KCl, 0.2 mM dNTPs, 1.5 mM MgCl₂, 0.6 μM forward and 0.6 μM reverse primers MOXM, CITM, CITM, DHAM, and DHAM; 0.5 μM primers ACCM, ACCM, EBCM, and EBCM, 0.4 μM primers FOXM and FOXM, and 1.25 U of Taq DNA polymerase (Qiagen, GmbH, Hilden, Germany)] and 5 μL of template DNA. PCR mixtures with the addition of water in place of template DNA were used as negative controls. The PCR program consisted of an initial denaturation step at 94°C for 3 minutes, followed by 25 cycles of DNA denaturation at 94°C for 30 seconds, primer annealing at 64°C for 30 seconds, and primer extension at 72°C for 1 minute. After the last cycle, a final extension step at 72°C for 7 minutes was added. PCR products (5 μL) were resolved in 2.5% agarose gel (Bio-Rad, Hercules, California, USA). Gels were stained with 10 μg/mL ethidium bromide and visualized by UV transillumination. A 100 bp DNA ladder (Gene DireX, USA) was used.

Multiplex PCR for the detection of ESBL genes
To detect the coexistence of ESBL genes, three primer pairs for screening the blaTEM, blaSHV and blaCTX-M genes were used in the PCR reaction. For further identification of the most prevalent ESBL types, the following primer pairs were used:CTX-M-3, CTX-M-14, and SHV-5.

Results
The antibiotic susceptibility of E. cloacae, C. freundii and S. marcescens is summarized in Table 2. Ceftazidime had variable activity against E. cloacae, C. freundii and S. marcescens with susceptibility rates of 53%, 60%, and 100%, respectively. Flomoxef was less active, with susceptibility rates of 10%, 10%, and 57%, respectively. Imipenem was the most active agent, with susceptibility rates of 97%, 100%, and 87%, respectively. Moxifloxacin had moderate activity, with susceptibility rates of 53%, 87%, and 67%, respectively. Colistin was the least active, with susceptible rates of 0%, 50%, and 0%, respectively.

Table 3 shows the number of isolates with the ESBL phenotype and related resistant genes. Nineteen E. cloacae isolates had a positive screening test for ceftazidime by the disk diffusion. Six E. cloacae isolates had a positive ESBL confirmatory test, and one of these six isolates carried ESBL genes. Thirteen E. cloacae isolates had a negative ESBL confirmatory test, and two of these carried ESBL genes. Only three of 19 E. cloacae isolates were detected by ESBL confirmatory test but four isolates were noted by the multiple PCR test in the following study (Table 4). Eighteen isolates had a positive screening test for ceftazidime by disk diffusion, while 16 were positive for by cefazidime broth microdilution. Five C. freundii isolates had a positive ESBL confirmatory test, and two carried an ESBL gene. Thirteen C. freundii isolates had a negative ESBL confirmatory test, and one of these 13 isolates carried ESBL genes. Four of 18 C. freundii isolates contained ampC genes. Among the 30 S. marcescens isolates, 16 had a positive screening test.
for cefotaxime by disk diffusion, while one had a positive screening test for ceftazidime by broth microdilution. Four *S. marcescens* isolates had a positive ESBL confirmatory test, and two of them carried ESBL genes. Twelve *S. marcescens* isolates had a negative ESBL confirmatory test, and no ESBL genes were detected. None of these 16 *S. marcescens* isolates carried ampC genes.

The isolates of *E. cloacae*, *C. freundii*, and *S. marcescens* with their resistance genes and related MICs for each of the five antibiotics are listed in Table 4. The *E. cloacae* isolate, E2, had an AmpC enzyme of the DHA type, and the TEM gene. The *E. cloacae* isolates, E3 and E14, had AmpC enzymes of the EBC type. The *E. cloacae* isolate, E5, had an AmpC enzyme of the EBC type, and the TEM gene. The *E. cloacae* isolate, E19, had only the TEM gene. All four of these isolates had low to high level resistance to ceftazidime with MICs ranging from 2 μg/mL to >32 μg/mL, and intermediate to medium level resistance to flomoxef with MICs ranging from 32 μg/mL to 128 μg/mL. The *S. marcescens* isolate, S2, had only the TEM gene. The *S. marcescens* isolate, S7, had both the TEM and CTX-M-3-like genes. These two isolates were susceptible to ceftazidime with MICs ranging from 1 μg/mL to 2 μg/mL, and were also susceptible to flomoxef with MICs ranging from 2 μg/mL to 16 μg/mL.

**Discussion**

Colistin was less active against the three species of *Enterobacteriaceae* in this study, although it displayed good activity against *Acinetobacter* spp., *Klebsiella* spp., and *E. coli* in the previous study. In a recent report, *Enterobacter* spp. showed low rates of susceptibility to the five fluoroquinolones: ciprofloxacin, ofloxacin, norfloxacin, levofloxacin, and gemifloxacin. In contrast, moxifloxacin showed moderate activity against the three species in this study, although cross-resistance was common in the ESBL-producing *Enterobacteriaceae*.

The E19 isolate of *E. cloacae* carried the TEM gene alone, and was resistant to both ceftazidime and flomoxef.
Flomoxef was less active than ceftazidime against both \textit{E. cloacae} and \textit{C. freundii} in this study. Flomoxef is an oxacephem antibiotic, and is supposed to be active against \textit{Enterobacteriaceae}, producing a TEM \(\beta\)-lactamase. Further work is necessary to determine whether this was a new \(\beta\)-lactamase capable of hydrolyzing cephamycins.

Among the 19 \textit{E. cloacae} isolates with a positive screening test for ESBL, four carried \textit{ampC} genes of either the DHA or EBC types. Among the 18 \textit{C. freundii} isolates with a positive screening test for ESBL, four carried an \textit{ampC} gene of the CIT type. All these isolates showed high-level resistance to flomoxef (MIC > 128 \(\mu\)g/mL). Hence, flomoxef resistance in combination with a positive ESBL screening test could serve as a sensitive indicator of AmpC enzyme production.

The screening and confirmatory tests have proven to be reliable for detecting the majority of conventional ESBLs, especially for variants of the TEM and SHV enzyme classes. We have tried our best to analyze the different ESBL types using six different primer pairs. The SHV gene was found in a \textit{C. freundii} isolate, the CTX-M-3-like gene was found in a \textit{C. freundii} isolate and in a \textit{S. marcescens} isolate. Previous studies show that SHV-12 is the predominant \textit{E. cloacae} ESBL type in Taiwan.\textsuperscript{7,13,23} In contrast, the percentage of SHV genes found in this study was less than that found in previous studies. This discrepancy could be due to the limited number of isolates used in this study, or to the different distribution of ESBL types in different hospitals. The TEM-1 gene was found to coexist with the SHV-12 gene in the 13 \textit{E. cloacae} isolates in studies by Yu et al and Ma et al.\textsuperscript{7,23} Three \textit{E. cloacae} isolates in this study were found to have the TEM class of \(\beta\)-lactamases. Identification of TEM types could be made by isoelectric focusing (IEF) and sequence analysis. However, this was beyond the scope of this study.

In a recent study conducted by the SENTRY Asia-Pacific surveillance program,\textsuperscript{24} 52 \textit{E. coli} isolates and 68 \textit{K. pneumoniae} isolates with negative ESBL confirmatory tests, as well as a comparable number of isolates with confirmed ESBL-positive tests, were examined for the presence of the TEM, SHV, plasmid-borne \textit{ampC}, and CTX-M genes. Interestingly, 62% of non-confirmed \textit{E. coli} isolates and 75% of non-confirmed \textit{K. pneumoniae} isolates harbored a plasmid-borne AmpC enzyme of the CIT or DHA type.
It is not uncommon for *Enterobacteriaceae* to carry multiple resistance genes. Among the 52 *E. coli* isolates with a non-confirmed ESBL test in the previously mentioned SENTRY Asia-Pacific surveillance program, 26 isolates (50%) carried AmpC+TEM enzymes. Similarly, this study showed that one isolate of *E. cloacae* had DHA+TEM enzymes while a second had EBC+TEM enzymes; two isolates of *C. freundii* had CIT+TEM+CTX-M-3-like enzymes, and CIT+TEM enzymes respectively. For the *Enterobacteriaceae* isolates carrying both the ESBL and AmpC enzymes, the phenotype appeared to be a positive screening test and negative confirmatory test. The AmpC enzyme can hydrolyze clavulanic acid, and thus make the confirmatory test negative. We also found 12 isolates of the three species with a positive screening test in which we were unable to detect any β-lactamase genes.

### Table 3. Number of isolates with the extended spectrum β-lactamase phenotype and related resistant genes

<table>
<thead>
<tr>
<th>Resistance genes</th>
<th><em>E. cloacae (n=30)</em></th>
<th><em>C. freundii (n=30)</em></th>
<th><em>S. marcescens (n=30)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive screening test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceftazidime&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Cefotaxime&lt;sup&gt;b&lt;/sup&gt;</td>
<td>19</td>
<td>18</td>
<td>16</td>
</tr>
<tr>
<td>Ceftazidime&lt;sup&gt;c&lt;/sup&gt;</td>
<td>15</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>ESBL confirmatory test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCT (gene)</td>
<td>6</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>With ESBL genes</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>With ampC genes</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>NCT (gene)</td>
<td>13</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>With ESBL genes</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>With ampC genes</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

<sup>a</sup>Disk diffusion (inhibition zone ≤ 22 mm); <sup>b</sup>disk diffusion (inhibition zone ≤ 27 mm); <sup>c</sup>broth dilution (MIC ≥ 2 μg). ESBL = extended spectrum β-lactamase; PCT = positive confirmatory test; NCT = negative confirmatory test.

### Table 4. The *Enterobacter cloacae*, *Citrobacter freundii*, and *Serratia marcescens* isolates with their resistance genes and related minimum inhibitory concentrations for the five antibiotics

<table>
<thead>
<tr>
<th>Resistance genes</th>
<th><em>E. cloacae</em></th>
<th><em>C. freundii</em></th>
<th><em>S. marcescens</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>ampC</em></td>
<td>DHA</td>
<td>EBC</td>
<td>EBC</td>
</tr>
<tr>
<td>ESBL</td>
<td>TEM</td>
<td>–</td>
<td>TEM</td>
</tr>
<tr>
<td>Confirmatory test</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>MICs (μg/mL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefazidime</td>
<td>2</td>
<td>16</td>
<td>256</td>
</tr>
<tr>
<td>Flomoxef</td>
<td>128</td>
<td>&gt;256</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Imipenem</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>1</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Colistin</td>
<td>8</td>
<td>&gt;256</td>
<td>16</td>
</tr>
</tbody>
</table>

MIC = Minimum inhibitory concentration; ESBL = extended spectrum β-lactamase.
isolates may produce enzymes not covered by the selected primer pairs, or may have mutations affecting the porin channels responsible for antimicrobial uptake.

The prevalence of AmpC-mediated resistance worldwide is not well known due to the limited number of surveillance studies for AmpC-producing isolates and the difficulty in accurately detecting these resistance mechanisms.\(^{11}\) The MYSTIC programs in Europe and the United States reported that the rates of \(ampC\) genes were much higher in \(Citrobacter\) spp. (9–25%) and \(Enterobacter\) spp. (13.8–29.2%) than in \(E. coli\) (0.6–2.8%) or \(Klebsiella\) spp. (0.5–4.5%).\(^{25}\) In our study, \(ampC\) genes were detected in 13.3% of \(E. cloacae\) and \(C. freundii\) isolates, but not in any of the \(S. marcescens\) isolates.

In a previous study, the coexistence of AmpC (\(DHA-1, CMY-2,\) or \(CMY-8\)) and ESBLs (\(CTX-M\) and/or \(SHV\)) was detected in 35 of 99 clinical \(K. pneumoniae\) isolates resistant to cefoxitin and extended-spectrum cephalosporins.\(^{36}\) The CMY-2-like \(\beta\)-lactamase was detected in 127 of 291 (43.6%) \(E. coli\) isolates. Among 282 \(K. pneumoniae\) isolates, the CMY-2-like and DHA-1-like \(\beta\)-lactamases were detected in 10 (3.5%) and 31 (11.0%) isolates, respectively.\(^{27}\)

The CIT primer pair amplifies the family-specific genes \(LAT-1\) to \(LAT-4\), \(CMY-2\) to \(CMY-7\), and \(BIL-1\). The DHA primer pair amplifies the family-specific genes \(DHA-1\) and \(DHA-2\).\(^{11}\) In our study, both CIT and DHA were detected in those resistant isolates by the screening primers. However, the specific subtypes need to be sequenced further, or subjected to IEF.

In summary, \(Enterobacteriaceae\) carry AmpC or ESBL enzymes that can be identified by a positive screening test and elevated MIC results. Positive confirmatory tests for ESBL indicate ESBL production. However, negative confirmatory tests do not exclude ESBL, but indicate the presence of \(ampC\) or a combination of \(ampC\) and ESBL. Antibiotic phenotypes cannot accurately distinguish between the resistance mechanisms caused by \(ampC\) or ESBL, especially where \(ampC\)-ESBL combinations are concerned. However, PCR is a useful technique for the identification of the different types of resistance genes.

**Acknowledgments**

We thank the staff in the Microbiology Laboratory at TCVGH for the collection of bacterial isolates.

**References**

15. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in
Multiplex PCR of AmpC

187


